Small Stocks, Big Money™

Phoenix Motor (Nasdaq: PEV), a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, announced its revenue guidance for the second quarter of 2024. The company expects to report revenue in the range of $14 million to $16 million, representing a significant increase from the $1.8 million recorded in the first quarter of 2023 and up from the expected $8 million to $9 million forecasted for Q1 2024, the company's previous record revenue quarter.

Spectaire Holdings (Nasdaq: SPEC), a pioneer in environmental measurement technology, signed a distribution partnership agreement with a Fortune 1000 Energy Company (the “Strategic Partner”). The Strategic Partner has been granted global distribution rights for the Company’s AireCore units for the oil and gas industry. Brian Semkiw, CEO of Spectaire, stated, "This collaboration with our Strategic Partner is a transformative step for Spectaire and the oil and gas industry at large. By integrating our state-of-the-art AireCore technology with the global reach and expertise of our partner, we're setting a new standard for environmental measurement and emissions reduction. Our technology's capability to precisely monitor and report emissions will be instrumental in helping the industry achieve its ambitious environmental goals. We are proud to work alongside a partner that shares our commitment to sustainability and innovation.”

Reviva Pharmaceuticals (Nasdaq: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced it has gained alignment with the U.S. Food and Drug Administration (FDA) on its registrational Phase 3 program for brilaroxazine in schizophrenia. The FDA accepted a 4-week RECOVER-2 study for brilaroxazine in schizophrenia. Notably, the FDA also indicated that two positive Phase 3 studies showing efficacy at week 4 that are accompanied by long-term safety data of at least 12 months could be supportive of an NDA submission for the acute treatment of schizophrenia. In addition, FDA indicated that it will require a long-term randomized withdrawal study post-approval to support maintenance of effect.

LOBO EV Technologies (Nasdaq: LOBO), an innovative electric vehicle manufacturer and seller, today announced it received strong interest from potential customers at the 135th China Import and Export Fair (“Canton Fair”), with more than 100 potential buyers visiting LOBO’s booth on the first day of the event. “We are thrilled by the overwhelming response our innovative solar-powered EVs have received at the 135th Canton Fair. The praise from both new and existing clients has been incredibly affirming, reflecting our commitment to advancing electric mobility,” stated Huajian Xu, CEO of LOBO. “Remarkably, we have secured approximately $1.2 million in new orders as of today from distributors at the exhibition who will resell our e-bikes in Eastern Europe, Southeast Asia, North America, and Latin America. Historically, the Canton Fair has consistently led to fruitful results, and this year is once again proving to be a major success.”